DISCLOSURE POLICY
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as an “ineligible company”, defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf of all other authors/contributors, if applicable.
Ineligible company: Any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition. |
Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. |
Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship. |
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.
For course-specific disclosure listings, please refer to the disclosure insert provided at your course site.
BTF TBI Planning/Development Committee Disclosures:
Eileen M. Bulger, MD, FACS
No relevant financial relationship(s) with ineligible companies to disclose
Jamshid Ghajar, MD, PhD, FACS
No relevant financial relationship(s) with ineligible companies to disclose
Gregory Hawryluk, MD, PhD
No relevant financial relationship(s) with ineligible companies to disclose
BTF TBI Author Disclosures:
Eric Sribnick, MD, FACS
No relevant financial relationship(s) with ineligible companies to disclose
Alan Hoffer, MD
No relevant financial relationship(s) with ineligible companies to disclose
Anthony Figaji, MD
No relevant financial relationship(s) with ineligible companies to disclose
Jamie S. Ullman, MD, FACS
No relevant financial relationship(s) with ineligible companies to disclose
Eve Tsai, MD, PhD, FRCSC, CIP
No relevant financial relationship(s) with ineligible companies to disclose
Andres Rubiano, MD, PhD
No relevant financial relationship(s) with ineligible companies to disclose
